Clinical trial · Interventional
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy : Expanded Access Clinical Study in 3 Arms
NCT06212440CI-TRIAL-00087196completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoadjuvant Therapy | — | UNRESOLVED | — |
| Sentinel Lymph Node Biopsy | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Indocyanine Green Fluorescence (ICG-F) Mapping | Diagnostic Test | — | UNRESOLVED |
| Radioactive Isotope (RI) Mapping | Diagnostic Test | — | UNRESOLVED |
| Vital Dye Mapping | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- RI + ICG-F
- description
- Participants undergo sentinel lymph node biopsy using Radioactive Isotope (RI) and Indocyanine Green Fluorescence (ICG-F) for lymphatic mapping.
- interventionNames
- Diagnostic Test: Radioactive Isotope (RI) Mapping
- Diagnostic Test: Indocyanine Green Fluorescence (ICG-F) Mapping
- type
- EXPERIMENTAL
- label
- RI + Vital Dye
- description
- Participants undergo sentinel lymph node biopsy using Radioactive Isotope (RI) and Vital Dye for lymphatic mapping.
- interventionNames
- Diagnostic Test: Radioactive Isotope (RI) Mapping
- Diagnostic Test: Vital Dye Mapping
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * The patient with locally advanced breast cancer who achieved neoadjuvant chemotherapy * Confirmed operability with imaging study after neoadjuvant chemotherapy * Age over 20 years old * ECOG Performance status : 0-2 * The patient with written informed consent form Exclusion Criteria: * The patient with previous ipsilateral breast cancer history * The patinet with previous ipsilateral axillary surgical procedure (e.g. excisional or incisional biopsy, axillary dissection) * The patient without neoadjuvant chemotherapy * Inoperable imaging study after neoadjuvant chemotherapy * Inflammatory breast cancer * Pregnant patient
References
Publications (0)
Data not yet available
No reference posted for this study.